CAP President Donald S. Karcher, MD, FCAP discusses the court’s LDT ruling. “For patients, this is incredibly good news. This means that labs will not be saddled with very high administrative burden or cost — all the things that regulation leads to," said Dr. Karcher.
For the full article click here: Judge foils FDA plan to regulate lab-developed tests